daurismo
pfizer europe ma eeig - glasdegib maleate - leukeemia, müeloidne, äge - antineoplastilised ained - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
kelevo tablett
livisto int'l s.l. - naatriumlevotüroksiin - tablett - 800mcg 250tk; 800mcg 50tk; 800mcg 100tk
kelevo tablett
livisto int'l s.l. - naatriumlevotüroksiin - tablett - 200mcg 100tk; 200mcg 50tk
kelevo tablett
livisto int'l s.l. - naatriumlevotüroksiin - tablett - 400mcg 100tk; 400mcg 250tk; 400mcg 50tk
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosupressandid - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukeemia, müeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
thyrotab tablett
cp-pharma handelsgesellschaft mbh - naatriumlevotüroksiin - tablett - 200mcg 100tk; 200mcg 30tk
thyrovet tablett
cp-pharma handelsgesellschaft mbh - naatriumlevotüroksiin - tablett - 800mcg 100tk; 800mcg 30tk
thyrovet tablett
cp-pharma handelsgesellschaft mbh - naatriumlevotüroksiin - tablett - 400mcg 250tk; 400mcg 30tk; 400mcg 100tk
thyrovet tablett
cp-pharma handelsgesellschaft mbh - naatriumlevotüroksiin - tablett - 200mcg 100tk; 200mcg 30tk; 200mcg 250tk